U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio

Reuters12-29 20:58
U.S. RESEARCH ROUNDUP-<a href="https://laohu8.com/S/EXPE">Expedia</a> Group, Hasbro, <a href="https://laohu8.com/S/PALI">Palisade Bio</a>

Dec 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Expedia Group, Hasbro and Palisade Bio on Monday.

HIGHLIGHTS

* Expedia Group Inc EXPE.O: Argus Research raises target price to $340 from $300

* Hasbro Inc HAS.O: Jefferies raises target price to $95 from $90

* Palisade Bio Inc PALI.O: Piper Sandler initiates coverage with overweight rating

* Praxis Precision Medicines Inc PRAX.O: BTIG raises target price to $843 from $507

* Vail Resorts Inc MTN.N: Truist Securities cuts target price to $234 from $237

Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order.

* Amicus Therapeutics Inc FOLD.O: Leerink Partners cuts target price to $14.50 from $17

* Amicus Therapeutics Inc FOLD.O: Leerink Partners cuts to market perform from outperform

* BP BP.N: Gerdes Energy Research cuts target price by $1 to $48

* Citigroup C.N: Piper Sandler raises target price to $130 from $120

* Expedia Group Inc EXPE.O: Argus Research raises target price to $340 from $300

* Hasbro Inc HAS.O: Jefferies raises target price to $95 from $90

* Palisade Bio Inc PALI.O: Piper Sandler initiates coverage with overweight rating

* Palisade Bio Inc PALI.O: Piper Sandler initiates coverage with price target $25

* Praxis Precision Medicines Inc PRAX.O: BTIG raises target price to $843 from $507

* Vail Resorts Inc MTN.N: Truist Securities cuts target price to $234 from $237

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment